BiotechTube
Apogee Biotechnology

Apogee Biotechnology

Hershey, United States· Est.
apogee-biotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18.4M

Overview

Apogee Biotechnology is a clinical-stage biotech developing first-in-class, oral sphingosine kinase (SK) inhibitors, with opaganib (ABC294640) as its lead asset. The company's platform targets a key enzyme in sphingolipid metabolism implicated in cancer proliferation, inflammation, and viral replication. Financed primarily through NIH SBIR and state grants, Apogee is advancing opaganib in Phase II trials for cholangiocarcinoma and prostate cancer, and has explored its use in COVID-19 due to anti-viral and anti-inflammatory properties.

OncologyInflammatory DiseasesAutoimmune DiseasesInfectious Disease

Technology Platform

Oral small molecule inhibitors of sphingosine kinase (SK), a key enzyme in sphingolipid metabolism that regulates cell proliferation, survival, and inflammation.

Funding History

42
Total raised:$18.4M
Grant$883K
Grant$852K
Grant$2.5M
Grant$225K

Opportunities

Opaganib's novel oral mechanism targeting sphingosine kinase offers a potential first-in-class therapy for high-unmet-need cancers like cholangiocarcinoma and a broad platform for inflammatory diseases.
Its demonstrated preclinical synergy with standard-of-care drugs creates significant combination therapy opportunities across multiple indications.

Risk Factors

The company faces high clinical risk with an unvalidated novel target in Phase II trials and significant financial risk due to heavy reliance on non-dilutive grant funding, which may be insufficient for late-stage development.
Intense competition in both oncology and inflammatory disease markets poses a major commercial challenge.

Competitive Landscape

In oncology, Apogee competes with a wide array of targeted therapies, chemotherapies, and immunotherapies. In inflammation, it faces entrenched competitors with approved biologics and JAK inhibitors. As a potential first-in-class SK inhibitor, its primary competition is other early-stage programs targeting the S1P pathway, though its specific SK2 inhibition and oral dosing may differentiate it.

More companies in Small Molecule Drugs →More companies in United States →